Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism
Abstract
Authors
M. Hamilton H. Phatak T. Lanitis J. Mardekian D.A. Rublee R. Leipold P. Quon C. Browne A.T. Cohen